Ankylosing spondylitis and non‑radiographic axial spondyloarthritis are part of a group of clinically heterogeneous inflammatory rheumatologic diseases known as spondyloarthritis. Spondyloarthritis ...

The alanto-axial joint is a joint which exists between the first and second vertebra of the cervical spine, the atlas and the axis. This is a complex joint made up of 3 joints which are all synovial ...

Spondyloarthritis encompasses a group of inflammatory conditions with some shared features, including extra-articular manifestations. Both peripheral and axial joints can be affected. The ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial ...

AbbVie announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq 15 mg, once daily) for the treatment of ...

Nr-axial SpA and ankylosing spondylitis (AS) come under the umbrella term of Axial Spondyloarthritis (axial SpA), [3] which is a painful and potentially progressive condition that mainly affects the ...

· New late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial ...

TORONTO, Oct. 19, 2020 /CNW/ - On October 14, 2020, Health Canada approved TALTZ® for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective ...

- RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3 This ...